

Cornelia Brunner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5485654/publications.pdf>

Version: 2024-02-01

67
papers

2,153
citations

304368

22
h-index

243296

44
g-index

68
all docs

68
docs citations

68
times ranked

3924
citing authors

#	ARTICLE	IF	CITATIONS
1	Bruton's Tyrosine Kinase Is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κ B Activation by Toll-like Receptor 4. <i>Journal of Biological Chemistry</i> , 2003, 278, 26258-26264.	1.6	260
2	Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 1454.	2.2	201
3	Cardiomyocyte-specific κ B kinase (IKK)/NF- κ B activation induces reversible inflammatory cardiomyopathy and heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 11794-11799.	3.3	150
4	NFATc1 affects mouse splenic B cell function by controlling the calcineurin-NFAT signaling network. <i>Journal of Experimental Medicine</i> , 2011, 208, 823-839.	4.2	109
5	Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1054-1067.e10.	1.5	105
6	Modulation of Calcium-Activated Potassium Channels Induces Cardiogenesis of Pluripotent Stem Cells and Enrichment of Pacemaker-Like Cells. <i>Circulation</i> , 2010, 122, 1823-1836.	1.6	102
7	Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. <i>Blood</i> , 2011, 117, 1329-1339.	0.6	97
8	The Ca ²⁺ -dependent Phosphatase Calcineurin Controls the Formation of the Carma1-Bcl10-Malt1 Complex during T Cell Receptor-induced NF- κ B Activation. <i>Journal of Biological Chemistry</i> , 2011, 286, 7522-7534.	1.6	89
9	TBX3 Directs Cell-Fate Decision toward Mesendoderm. <i>Stem Cell Reports</i> , 2013, 1, 248-265.	2.3	72
10	HSP90 Supports Tumor Growth and Angiogenesis through PRKD2 Protein Stabilization. <i>Cancer Research</i> , 2014, 74, 7125-7136.	0.4	52
11	BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses. <i>EMBO Journal</i> , 2007, 26, 3191-3202.	3.5	48
12	The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4072.	1.8	48
13	NF- κ B and Its Role in Checkpoint Control. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3949.	1.8	45
14	The transcriptional coactivator Bob1 promotes the development of follicular T helper cells via Bcl6. <i>EMBO Journal</i> , 2016, 35, 881-898.	3.5	44
15	B Cell-specific Transgenic Expression of Bcl2 Rescues Early B Lymphopoiesis but Not B Cell Responses in BOB.1/OBF.1-deficient Mice. <i>Journal of Experimental Medicine</i> , 2003, 197, 1205-1211.	4.2	42
16	Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 19, 194-201.	1.3	41
17	Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation. <i>Neuro-Oncology</i> , 2011, 13, 710-724.	0.6	36
18	Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer. <i>Oncoscience</i> , 2018, 5, 75-87.	0.9	36

#	ARTICLE	IF	CITATIONS
19	The role of transcription factors in the guidance of granulopoiesis. American Journal of Blood Research, 2012, 2, 57-65.	0.6	36
20	The dynactin p150 subunit: cell biology studies of sequence changes found in ALS/MND and Parkinsonian Syndromes. Journal of Neural Transmission, 2013, 120, 785-798.	1.4	35
21	Immune Suppressive Effects of Plasma-Derived Exosome Populations in Head and Neck Cancer. Cancers, 2020, 12, 1997.	1.7	27
22	Ca ²⁺ Activated K Channels-New Tools to Induce Cardiac Commitment from Pluripotent Stem Cells in Mice and Men. Stem Cell Reviews and Reports, 2012, 8, 720-740.	5.6	24
23	Adenosine-producing regulatory B cells in head and neck cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1205-1216.	2.0	24
24	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	0.8	21
25	Bruton's Tyrosine Kinase is Activated upon CD40 Stimulation in Human B Lymphocytes. Immunobiology, 2002, 206, 432-440.	0.8	20
26	Btk expression is controlled by Oct and BOB.1/OBF.1. Nucleic Acids Research, 2006, 34, 1807-1815.	6.5	19
27	Octamer-dependent transcription in T cells is mediated by NFAT and NF- κ B. Nucleic Acids Research, 2013, 41, 2138-2154.	6.5	19
28	Circulating Exosomes Inhibit B Cell Proliferation and Activity. Cancers, 2020, 12, 2110.	1.7	19
29	The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma. Oncotarget, 2018, 9, 5834-5847.	0.8	19
30	MyD88 is involved in myeloid as well as lymphoid hematopoiesis independent of the presence of a pathogen. American Journal of Blood Research, 2013, 3, 124-40.	0.6	19
31	Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5181.	1.8	17
32	Protein Kinase D2 Is an Essential Regulator of Murine Myoblast Differentiation. PLoS ONE, 2011, 6, e14599.	1.1	17
33	Role of the adipocyte-specific NF- κ B activity in the regulation of IP-10 and T cell migration. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E304-E311.	1.8	16
34	The Potential of CD16 on Plasma-Derived Exosomes as a Liquid Biomarker in Head and Neck Cancer. International Journal of Molecular Sciences, 2020, 21, 3739.	1.8	16
35	Expression of the Aldehyde Dehydrogenase 2-like Gene Is Controlled by BOB.1/OBF.1 in B Lymphocytes. Journal of Biological Chemistry, 2003, 278, 45231-45239.	1.6	15
36	Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells. International Journal of Cancer, 2020, 147, 202-217.	2.3	15

#	ARTICLE	IF	CITATIONS
37	Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5990.	1.8	14
38	Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1335.	1.7	14
39	Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 247.	1.8	14
40	Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2019, 25, 7405-7412.	3.2	13
41	Increasing Mean Age of Head and Neck Cancer Patients at a German Tertiary Referral Center. <i>Cancers</i> , 2021, 13, 832.	1.7	13
42	Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. <i>Carcinogenesis</i> , 2020, 41, 1421-1431.	1.3	12
43	Bradykinin signaling regulates solute permeability and cellular junction organization in lymphatic endothelial cells. <i>Microcirculation</i> , 2020, 27, e12592.	1.0	10
44	BOB.1/OBF.1 - A Critical Regulator of B Cell Function. <i>Current Immunology Reviews</i> , 2006, 2, 3-12.	1.2	9
45	Cargo and Functional Profile of Saliva-Derived Exosomes Reveal Biomarkers Specific for Head and Neck Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	9
46	Allele-specific quantitative proteomics unravels molecular mechanisms modulated by cis-regulatory PPARC locus variation. <i>Nucleic Acids Research</i> , 2017, 45, 3266-3279.	6.5	8
47	Polyfunctionality of CD4+ TÂlymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 392-402.	1.0	8
48	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. <i>International Journal of Cancer</i> , 2019, 145, 3436-3444.	2.3	8
49	The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5875.	1.8	8
50	NFâ€Bâ€dependent signals control BOB.1/OBF.1 and Oct2 transcriptional activity in B cells. <i>European Journal of Immunology</i> , 2015, 45, 3441-3453.	1.6	7
51	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). <i>International Journal of Cancer</i> , 2021, 148, 2023-2035.	2.3	6
52	Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia. <i>Journal of Clinical Immunology</i> , 2002, 22, 244-251.	2.0	5
53	Myosin light chain 1 atrial isoform (MLC1A) is expressed in pre-B cells under control of the BOB.1/OBF.1 coactivator. <i>Nucleic Acids Research</i> , 2004, 32, 1577-1583.	6.5	5
54	Enhanced cellular migration and prolonged chondrogenic differentiation in decellularized cartilage scaffolds under dynamic culture conditions. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2022, 16, 36-50.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Patterns of Tumor Infiltrating Lymphocytes in Adenoid Cystic Carcinoma of the Head and Neck. <i>Cancers</i> , 2022, 14, 1383.	1.7	5
56	BOB.1/OBF.1 is required during Bâ€cell ontogeny for Bâ€cell differentiation and germinal center function. <i>European Journal of Immunology</i> , 2022, 52, 404-417.	1.6	5
57	Immunotherapy for head and neck cancers: an update and future perspectives. <i>Immunotherapy</i> , 2019, 11, 561-564.	1.0	4
58	Analysis, identification and visualization of subgroups in genomics. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	4
59	Impaired Peyer's patch development in BOB.1/OBF.1â€deficient mice. <i>European Journal of Immunology</i> , 2021, 51, 1860-1863.	1.6	4
60	T Cell Specific BOB.1/OBF.1 Expression Promotes Germinal Center Response and T Helper Cell Differentiation. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
61	Differential Requirement of Vav Proteins for Btk-dependent and â€Independent Signaling During B Cell Development. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 654181.	1.8	2
62	CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6551-6551.	0.8	1
63	Editorial: Targeting Bruton Tyrosine Kinase. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 909655.	1.8	1
64	Abstract 5129: Role of PRKD2 in HSP90 inhibition-mediated suppression of cancer growth. , 2014, , .		0
65	Abstract 1435: Role of PRKD2 in HSP90- and hypoxia-mediated epithelial-to-mesenchymal transition. , 2015, , .		0
66	Analysis of the influence of adenosine on HNSCC cell lines. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, .	0.2	0
67	Immune checkpoint expression on lymphocyte populations in head and neck cancer patients. , 2018, 97, .		0